Troculeucel

2026肺癌治愈冲刺：21款新药+6大免疫突破，锁定8大靶点 面对癌细胞，手中武器的数量和质量，直接决定生命的长度和亮度。 全球每年新增肺癌病例超过220万例，死亡人数近180万，中国的新发和死亡病例均占全球四成以上。一串串冰冷的数字背后，是无数家庭的挣扎与期盼。 而就在刚刚过去的2025年，肺癌治疗领域迎来了前所未有的“武器大升级”——中美两国密集批准了超过21款靶向与免疫新药，一举将8大核心致癌靶点纳入精准打击范围。 同时，6大免疫“黑科技” 已从实验室疾驰向临床，准备为“治愈”按下加速键。这不再是一场绝望的消耗战，而是一次目标清晰、弹药充足的战略总攻。 01 死神仍在徘徊：肺癌治疗，我们到底面临哪些“硬骨头”？ 肺癌之所以凶险，首先在于它的“狡猾”与“复杂”。许多病友和家属在确诊之初，往往被几个根本性的难题困住。 第一大难题：发现即晚期。 肺癌早期症状隐匿，超过70% 的患者在确诊时已进入中晚期，癌细胞可能已扩散至淋巴结或远处器官，根治性手术机会瞬间丧失。 第二大难题：基因突变的“多样性”与“进化性”。 肺癌并非一种病，而是一组由不同基因突变驱动的疾病。除了常见的EGFR、ALK，还有KRAS、MET、ROS1、RET、BRAF、HER2等众多靶点。 更棘手的是，癌细胞会“学习”和“进化”。即便初始治疗有效，它们也可能产生新的耐药突变，让原来的特效药逐渐失灵。 第三大难题：传统治疗的“双刃剑”效应。 化疗“敌我不分”，在杀伤癌细胞的同时也重创了免疫系统，导致患者身体虚弱，难以持续作战。放疗则受限于局部，对远处转移灶束手无策。 第四大难题：“免疫静默”的困境。 部分患者的肿瘤非常“聪明”，能给自己戴上“伪装面具”，并释放信号抑制人体免疫T细胞的活性，使其无法识别和攻击癌细胞，导致免疫药物对这部分患者效果不佳。 这些“硬骨头”，共同构成了肺癌治愈之路上的重重关隘。过去，医疗手段有限，许多患者和医生面临“巧妇难为无米之炊”的窘境。但现在，情况正在发生根本性的改变。 02 治愈的曙光：从“无药可医”到“精准打击”，肺癌治疗理念如何颠覆？ 治疗困局的突破，始于对癌细胞认知的深化和打击策略的革新。现代肺癌治疗已经告别了“一刀切”的蛮荒时代，进入了 “精准制导”与“智慧免疫” 并行的新纪元。 核心理念一：靶向治疗——为你的癌症配上专属的“钥匙”。 如果把致癌的基因突变比作驱动癌细胞疯狂生长的 “错误开关” ，那么靶向药就是专门设计来关闭这个开关的 “精准钥匙”。 它只作用于带有特定突变的癌细胞，对正常细胞影响很小。从第一代到第三代，靶向药不断迭代，目的就是为了更准、更狠地锁定目标，并尽力延迟耐药的发生。 核心理念二：免疫治疗——唤醒你体内沉睡的“警卫军团”。 如果说靶向治疗是借助“外援”，那么免疫治疗则是激发自身潜力。我们的免疫系统本应是强大的抗癌军队，但肿瘤微环境会释放“刹车信号”使其沉睡。 以PD-1/PD-L1抑制剂为代表的免疫检查点抑制剂，其作用就是松开这个“刹车”，让患者自身的免疫T细胞重新识别并猛烈攻击癌细胞，甚至产生“长效记忆”，实现长期控制。 核心理念三：联合治疗——“海陆空”协同作战。 单一兵种作战有其局限。现在的趋势是将不同机制的武器组合使用：靶向药联合抗血管生成药、免疫药联合化疗、双免疫联合、乃至最新的“靶向+免疫”等方案。 这种联合作战模式，能从多通路、多维度打击肿瘤，大幅提升疗效，并将部分晚期患者的五年生存率提升了数倍。 理念的颠覆，直接催生了武器的井喷。2025-2026年，正是这些新理念结出累累硕果的爆发期。 03 破局之战：2026，我们手握哪些“抗癌武器库”？ 这是肺癌治疗史上武器最丰富、火力最强大的时刻。我们将这些新武器分为两大阵营：精准靶向阵营与免疫增强阵营。精准靶向阵营：21款新药，覆盖8大核心靶点 基于您提供的核心数据，以下是对2025年获批及2026年即将上市的关键药物的战略梳理： 1. EGFR靶点：王牌靶点，纵深防御体系已成这是亚洲患者最常见的突变靶点。如今，我们已建立起从一线到后线的立体化防御网。 一线主力：除了经典的奥希替尼，2025年新获批的利厄替尼片、马来酸美凡厄替尼片为EGFR常见突变患者提供了新的高效一线选择。 攻坚“堡垒”：针对昔日最难治的EGFR 20号外显子插入突变，我们迎来了双特异性抗体“埃万妥单抗” 和新型TKI“舒沃替尼”，打破了无药可用的僵局。 耐药后策略：针对奥希替尼耐药后出现的MET扩增等复杂情况，埃万妥单抗联合方案已获批，提供了明确的后续路径。 2. ALK/ROS1靶点：“钻石突变”，追求更长生存这两个靶点药物研发竞争激烈，患者生存期不断刷新纪录。 ALK新秀：2025年，国产新药地罗阿克片加入一线战场，为患者提供了又一利器。劳拉替尼等后线药物则牢牢守住最后防线。 ROS1新突破：他雷替尼在中美双双获批，因其对脑转移效果显著，成为该靶点治疗的新标杆。 3. KRAS靶点：“不可成药”神话被彻底终结从无药可用到百花齐放，KRAS G12C突变患者迎来了春天。继阿达格拉西布、索拖拉西布之后，2025年国产枸橼酸戈来雷塞片获批，为经治患者提供了优质选择，且更多KRAS抑制剂正在路上。 4. MET、RET、BRAF、HER2等罕见靶点：告别“罕见”，迎来“阳光”这些曾经让医生摇头的罕见突变，如今都有了对应用药。 MET：赛沃替尼、卡马替尼之后，新型抗体偶联药物（ADC）Teliso-V和伯瑞替尼肠溶胶囊（针对MET扩增）在2025年获批，丰富了治疗层次。 HER2：2025年是肺癌HER2突变的“突破年”。宗格替尼、注射用瑞康曲妥珠单抗等药物接连获批，标志着该靶点正式进入精准靶向时代。2026年备受期待的塞瓦替尼也已进入上市倒计时。 RET：塞尔帕替尼、普雷西替尼已奠定坚实基础。 NTRK、TROP2等：拉罗替尼等广谱抗癌药，以及靶向TROP2的ADC药物德达博妥单抗、芦康沙妥珠单抗，为特定患者提供了“跨癌种”或后线的有力武器。免疫增强阵营：6大“黑科技”，从辅助到前沿 除了直接杀伤肿瘤，现代医学正通过前沿技术系统性改造患者的免疫内环境，为治愈创造可能。 黑科技1：治疗性疫苗——训练免疫系统的“特战教官”如古巴CIMAvax-EGF疫苗，它不直接杀死癌细胞，而是教会免疫系统持续识别并攻击携带EGF的癌细胞，像一位永不懈怠的教官，尤其适合无驱动基因突变的患者，用于维持治疗，显著延长生存期。 黑科技2：过继性细胞疗法——输注“超级免疫士兵” TIL疗法：直接从患者肿瘤组织中分离出能识别癌细胞的免疫细胞（TIL），在体外大量扩增、激活后回输。如GC101在临床试验中对多线治疗失败的晚期肺癌仍显示出高缓解率，是攻坚晚期难治性肿瘤的“特种部队”。 NK细胞疗法：如SNK01自体NK细胞疗法，通过回输大量活化的自然杀伤细胞，恢复免疫系统的先天杀伤能力，与化疗、靶向药联用可大幅提升疗效。 黑科技3：电场疗法——穿戴式“细胞分裂干扰器”通过贴在胸部的换能器阵列产生低强度交变电场，干扰癌细胞分裂，导致其死亡。这是一种无创、可居家进行的物理疗法，尤其对局部肿瘤控制效果好，为患者提供了一种全新的治疗选择。 黑科技4：肠道菌群调节——夯实免疫“大后方”最新研究明确，肠道菌群健康直接影响免疫治疗和化疗的效果。通过补充特定的益生菌制剂，可以优化免疫微环境，提升治疗应答率，降低副作用，是性价比极高的“免疫加速器”。 黑科技5：双特异性抗体/双免疫——“双靶点”精确制导与“双重解刹” 埃万妥单抗即是同时靶向EGFR和MET的双抗典范。 在免疫领域，“O+Y”（纳武利尤单抗联合伊匹木单抗）这类双免疫方案，通过同时解除PD-1和CTLA-4两个免疫刹车，产生了更强的协同激活效应，已在特定肺癌患者中确立地位。 黑科技6：抗体偶联药物——生物“精确制导导弹”以德达博妥单抗、芦康沙妥珠单抗为代表。这类药物由靶向癌细胞的抗体、细胞毒药物和连接子三部分构成。抗体像“导航头”精准定位肿瘤，细胞毒药物则是高效“弹头”，能极大提高杀伤效率并降低全身毒性，是未来发展的核心方向之一。 04 致每一位斗士：从“幸存”到“新生”，抗癌思维的终极进化 武器已经备好，但打赢这场战争，更需要战略和信念的升级。面对2026年的全新格局，每一位患者和家属都需要完成以下关键认知的进化： 认知一：治疗“规范化”是生命线的基石。 永远不要轻视首次治疗。确诊后，务必进行全面的基因检测（组织+血液，广谱NGS panel），明确病理分型和全部突变信息。这是决定你走上哪条最优治疗路径的“导航图”。盲目试药或迷信偏方，只会贻误最宝贵的战机。 认知二：治疗“动态化”是应对耐药的智慧。 抗癌是持久战，耐药是多数人终将面对的课题。这并非末日，而只是战役进入了新阶段。此时，再次进行基因检测，明确耐药机制，就能找到下一个有效的靶向药或联合方案。从一线、二线到后线，治疗方案已形成接续链条。 认知三：治疗“整体化”是长治久安的保障。 抗癌不等于只看肿瘤指标。营养支持、心理调节、免疫维护、适度锻炼与药物治疗同等重要。一个营养良好、心态积极、免疫系统得到呵护的身体，才是承受各项治疗并最终战胜疾病的根本平台。 认知四：“临床治愈”已成为可追求的目标。 对于早期患者，通过手术和辅助治疗，治愈是大概率事件。对于晚期患者，通过靶向、免疫等综合治疗，实现肿瘤长期缩小、稳定，带瘤高质量生存五年、十年以上的患者越来越多。“与癌共舞，长期生存”就是另一种形式的胜利。 2026年，我们站在肺癌治疗史上一个前所未有的高点上。层出不穷的新药和新技术，正将肺癌从一个“绝症”逐渐推向“可防、可治、可控”的慢性病范畴。 这不是盲目乐观，而是基于科学进展的理性判断。希望，来自于手中实实在在的武器，更来自于心中永不放弃的信念。 你怎么看？欢迎在评论区留下你的观点。 如果觉得有用，请点赞+在看，支持我们！ 注：【愈她他同行】目前有肺癌、肝癌、肾癌、胃癌、 肠癌、胰腺癌、妇瘤、泌尿肿瘤、血液肿瘤......等几乎涵盖所有癌种的临床试验 正在招募患者！扫描下方二维码 添加医学助理一对一咨询！ 愈她他同行与您同行，共创健康未来。 参与临床试验，获取国际前沿新药 免费使用机会！ 更有一线专家团队为您的治疗 保驾护航！ end 全国癌症病友交流群，为您提供全方位的支持与交流平台: 具体包括： 呼吸系统肺癌病友交流群：小细胞肺癌，非小细胞肺癌（肺腺癌、肺鳞癌）... 消化系统癌症病友群：胃癌、肠癌、肝癌、胆管癌、胰腺癌、胆囊癌、食管癌、贲门癌... 妇科癌症病友群：乳腺癌、宫颈癌、卵巢癌、外阴癌、子宫内膜癌、输卵管癌... 泌尿系统癌症病友群：肾癌、前列腺癌、膀胱癌、尿路上皮癌、睾丸癌。阴茎癌... 头颈癌病友群：鼻咽癌、甲状腺癌，舌癌、口腔癌、胶质瘤... 血液癌病友群：淋巴瘤、白血病交流群... 罕见病病友群：胸腺瘤、平滑肌瘤，恶性脂肪瘤、黑色素瘤…… end 您的赞+在看+分享是我更新的动力！ 也能帮到更多病友，积极关注、分享能积福接好运哦！ 愿每个人都能早日康复！ 分享 收藏 点赞 在看

Dr. Miller’s appointment further enhances NKGen’s scientific and clinical advisory capabilities as the Company advances its research in Alzheimer’s and other related neurodegenerative diseases. SANTA ANA, Calif., January 22, 2026 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer’s disease (“AD”), frontotemporal dementia (“FTD”), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the University of California, San Francisco (“UCSF”) where he directs the Edward and Pearl Fein Memory and Aging Center and is the founding director of the Global Brain Health Institute. His career spans decades at the forefront of clinical care, research, and education in neurodegenerative disease, advancing understanding of the brain-behavior relationship, the genetic and molecular foundations of dementia, and precision-medicine approaches for tauopathies and FTD-related conditions. “We are honored to welcome Dr. Miller to our Scientific Advisory Board. His global leadership in neurodegeneration research and his long-standing contributions to the Alzheimer’s and FTD fields bring a level of expertise that will meaningfully inform our clinical and scientific priorities as we continue to execute our development strategy, including our ongoing Phase 2 clinical trial evaluating our autologous NK cell therapy candidate, troculeucel, in individuals with moderate Alzheimer’s disease. We also look to leverage his expertise to further explore the use of troculeucel in FTD, where we have seen some very promising early signals in patients treated under expanded access,” said Paul Y. Song, M.D., Chairman and CEO of NKGen Biotech. “ Dr. Miller has published more than 2,000 peer-reviewed articles, authored seminal books including The Behavioral Neurology of Dementia and Frontotemporal Dementia, and contributed to defining the clinical and biological boundaries between Alzheimer’s disease, FTD, and other neurodegenerative disorders. He has also played a central role in major research collaborations, including work with the Tau Consortium and the Bluefield Foundation, which support the development of potential therapies for tauopathies and progranulin-mediated FTD. About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com. Forward-Looking Statements Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s anticipated timing and content of its filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public disclosures; the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. Additional risks include uncertainties related to the Company’s acquisition of a majority interest in NKGen Biotech Korea Co., Ltd., including risks regarding the future performance of NKGen Biotech Korea Co., Ltd.’s business, the Company’s ability to successfully integrate NKGen Biotech Korea Co., Ltd.’s operations, personnel, and technologies, potential challenges in realizing expected synergies and cost savings, and risks that the Company may not achieve the anticipated strategic, financial, or operational benefits of the acquisition on the expected timeline or at all. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the SEC’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact: Denise Chua, MBA, CLS, MLS (ASCP) SVP, Corporate Affairs 949-396-6830 dchua@nkgenbiotech.com External Contact: Kevin Gardner Managing Director LifeSci Advisors, LLC kgardner@lifesciadvisors.com